tradingkey.logo

BRIEF-Adial Pharma Receives Positive Response From FDA Meeting Regarding Vitro Bridging Strategy For AD04

ReutersFeb 25, 2025 2:43 PM

- Adial Pharmaceuticals Inc ADIL.O:

  • ADIAL PHARMACEUTICALS RECEIVES POSITIVE RESPONSE FROM FDA MEETING REGARDING PROPOSED IN VITRO BRIDGING STRATEGY FOR AD04

  • ADIAL PHARMACEUTICALS- MOVES FORWARD WITH MANUFACTURING CLINICAL SUPPLIES FOR PHASE 3 PROGRAM IN 2025

Source text: ID:nGNX9ZpY9Q

Further company coverage: ADIL.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI